Fox News |
FDA slaps cardiovascular warnings on Roche/Novartis asthma blockbuster Xolair
FiercePharma It was way back in 2009 when the FDA first indicated it was worried about reports of heart attacks and strokes in patients taking Xolair, the asthma treatment co-marketed by Novartis ($NVS) and Roche ($RHHBY). Now the agency is taking action, slapping … FDA says asthma drug Xolair raises risk of heart, brain problems Heart, Mini-Stroke Risks From Asthma Drug: FDA FDA adds cardiovascular risks to Xolair label for asthma treatment |
View full post on asthma – Google News